Radiopharmaceuticals for lymphoscintigraphy: including dosimetry and radiation considerations

Area of Science:

• Nuclear medicine
• Oncology
• Radiopharmacology

Background:

• Lymphoscintigraphy is vital for sentinel lymph node (SLN) identification in melanoma and breast cancer management.
• Clinical acceptance of SLN biopsy is high, yet no single radiopharmaceutical agent is universally agreed upon.
• This leads to diverse clinical use of various agents and ongoing development of new ones.

Purpose of the Study:

• To review the essential physical properties of radiopharmaceutical agents for lymphoscintigraphy.
• To discuss commonly used and developing radiopharmaceutical agents.
• To analyze the dosimetry and biological effects of these agents in the context of melanoma and breast cancer.

Main Methods:

• Literature review of physical properties, clinical applications, and dosimetry of radiopharmaceutical agents.
• In-depth discussion of currently used agents.
• Overview of agents under development.

Main Results:

• Various radiopharmaceutical agents are used clinically, each with distinct physical properties, dosimetry, and biological effects.
• No definitive consensus exists on the optimal agent for lymphoscintigraphy.
• Several agents are under investigation, aiming to improve diagnostic accuracy and safety.

Conclusions:

• Optimal selection of radiopharmaceutical agents for lymphoscintigraphy requires careful consideration of physical properties, dosimetry, and biological impact.
• Further research and consensus are needed to establish the ideal agent for SLN identification in cancer patients.
• This review provides a comprehensive overview to aid clinicians and researchers in agent selection and development.